WallStreetZenWallStreetZen

NASDAQ: GMAB
Genmab A Stock Forecast, Predictions & Price Target

Open Broker Account
OverviewForecast
EarningsDividendOwnership

Analyst price target for GMAB

Based on 5 analysts offering 12 month price targets for Genmab A.
Min Forecast
$33.00-27.14%
Avg Forecast
$38.15-15.77%
Max Forecast
$51.00+12.61%

Should I buy or sell GMAB stock?

Based on 7 analysts offering ratings for Genmab A.
Hold
Strong Buy
0 analysts 0%
Buy
1 analysts 14.29%
Hold
5 analysts 71.43%
Sell
0 analysts 0%
Strong Sell
1 analysts 14.29%

Be the first to know when Wall Street analysts revise their GMAB stock forecasts and price targets.

GMAB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
William Blair
Bottom 3%
3
HoldInitiates Coverage OnN/AN/A2022-11-14
Morgan Stanley
Bottom 3%
3
Strong SellMaintains$34.00-24.93%2022-11-14
SVB Leerink
Bottom 2%
2
HoldMaintains$33.00-27.14%2022-11-10
HC Wainwright & Co.
Bottom 1%
1
BuyMaintains$51.00+12.61%2022-08-22
BMO Capital
Top 9%
92
HoldInitiates Coverage On$34.73-23.32%2022-06-24
Anonymous
Morgan Stanley
Strong SellMaintains$29.00-35.97%2022-05-17
Cowen & Co.
Bottom 5%
5
HoldInitiates Coverage On$38.00-16.10%2022-05-02
Guggenheim
Top 11%
90
HoldDowngradesN/AN/A2022-01-03

1 of 1

Forecast return on equity

Is GMAB forecast to generate an efficient return?
Company
4.48%
Industry
15.35%
Market
62.84%
GMAB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is GMAB forecast to generate an efficient return on assets?
Company
3.89%
Industry
13.55%
GMAB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

GMAB earnings per share forecast

What is GMAB's earnings per share in the next 3 years based on estimates from 8 analysts?
Avg 1 year Forecast
$1.00-10.71%
Avg 2 year Forecast
$1.23+9.82%
Avg 3 year Forecast
$1.65+47.32%
GMAB's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

GMAB revenue forecast

What is GMAB's revenue in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$1.8B+12.81%
Avg 2 year Forecast
$2.3B+50.24%
Avg 3 year Forecast
$2.8B+80.23%
GMAB's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

GMAB earnings growth forecast

How is GMAB forecast to perform vs Biotechnology companies and vs the US market?
Company
11.83%
Industry
7.94%
Market
17.02%
GMAB's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
GMAB's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
GMAB's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

GMAB revenue growth forecast

How is GMAB forecast to perform vs Biotechnology companies and vs the US market?
Company
21.18%
Industry
24.83%
Market
6.69%
GMAB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
GMAB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

GMAB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
GMAB$45.29$38.15-15.77%Hold
ALNY$219.64$226.31+3.04%Buy
RPRX$41.93$52.67+25.61%Strong Buy
SGEN$117.91$163.83+38.95%Buy
ARGX$385.54$436.42+13.20%Strong Buy
View Top Biotech Stocks

Genmab A Stock Forecast FAQ

Is Genmab A Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 7 Wall Street analysts covering (NASDAQ: GMAB) stock is to Hold GMAB stock.

Out of 7 analysts, 0 (0%) are recommending GMAB as a Strong Buy, 1 (14.29%) are recommending GMAB as a Buy, 5 (71.43%) are recommending GMAB as a Hold, 0 (0%) are recommending GMAB as a Sell, and 1 (14.29%) are recommending GMAB as a Strong Sell.

If you're new to stock investing, here's how to buy Genmab A stock.

What is GMAB's earnings growth forecast for 2022-2024?

(NASDAQ: GMAB) Genmab A's forecast annual earnings growth rate of 11.83% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 7.94%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.02%.

Genmab A's earnings in 2022 is $747,883,597.On average, 8 Wall Street analysts forecast GMAB's earnings for 2022 to be $65,829,282, with the lowest GMAB earnings forecast at $60,562,939, and the highest GMAB earnings forecast at $74,387,089. On average, 7 Wall Street analysts forecast GMAB's earnings for 2023 to be $80,970,017, with the lowest GMAB earnings forecast at $64,512,696, and the highest GMAB earnings forecast at $95,452,459.

In 2024, GMAB is forecast to generate $108,618,315 in earnings, with the lowest earnings forecast at $96,769,045 and the highest earnings forecast at $115,859,536.

What is GMAB's revenue growth forecast for 2022-2024?

(NASDAQ: GMAB) Genmab A's forecast annual revenue growth rate of 21.18% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 24.83%, and while it is forecast to beat the US market's average forecast revenue growth rate of 6.69%.

Genmab A's revenue in 2022 is $1,585,582,010.On average, 5 Wall Street analysts forecast GMAB's revenue for 2022 to be $115,304,595,473, with the lowest GMAB revenue forecast at $104,051,079,715, and the highest GMAB revenue forecast at $124,418,001,273. On average, 5 Wall Street analysts forecast GMAB's revenue for 2023 to be $153,566,680,708, with the lowest GMAB revenue forecast at $142,324,224,270, and the highest GMAB revenue forecast at $166,393,384,647.

In 2024, GMAB is forecast to generate $184,224,891,409 in revenue, with the lowest revenue forecast at $171,236,444,924 and the highest revenue forecast at $211,163,879,336.

What is GMAB's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: GMAB) forecast ROA is 3.89%, which is lower than the forecast US Biotechnology industry average of 13.55%.

What is GMAB's Price Target?

According to 5 Wall Street analysts that have issued a 1 year GMAB price target, the average GMAB price target is $38.15, with the highest GMAB stock price forecast at $51.00 and the lowest GMAB stock price forecast at $33.00.

On average, Wall Street analysts predict that Genmab A's share price could fall to $38.15 by Nov 14, 2023. The average Genmab A stock price prediction forecasts a potential downside of 15.77% from the current GMAB share price of $45.29.

What is GMAB's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: GMAB) Genmab A's current Earnings Per Share (EPS) is $1.14. On average, analysts forecast that GMAB's EPS will be $1.00 for 2022, with the lowest EPS forecast at $0.92, and the highest EPS forecast at $1.13. On average, analysts forecast that GMAB's EPS will be $1.23 for 2023, with the lowest EPS forecast at $0.98, and the highest EPS forecast at $1.45. In 2024, GMAB's EPS is forecast to hit $1.65 (min: $1.47, max: $1.76).

What is GMAB's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: GMAB) forecast ROE is 4.48%, which is considered weak.
©2022 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.